

RESOLUTION 09.2019-11 (A-20)
FEDERAL INITIATIVE TO TREAT CANNABIS DEPENDENCE

ISMS Board Action Taken on 10/26/2019

Adopted Resolution 09.2019-11 (A-20), as amended by the Council on Medical Service (with title change).

Council on Medical Service Recommendation to ISMS Board on 10/26/2019

The resolution's author informed the Council that there is currently no FDA-approved medication to treat cannabis dependence, and opined that the cost of development should be covered by a federal tax on the marijuana industry. The Council believes it important that efficacious medicines be developed but also that options beyond medications be explored. The Council noted that there can be no federal tax on marijuana as long as it is federally illegal. Concern was also voiced that the resolved clauses did not stand alone. Thus, the Council recommended that the Board adopt an amended resolution with more inclusive language and that the title be changed to focus on federal efforts to develop medication.

The Council on Medical Service recommends that the ISMS Board of Trustees adopt Resolution 09.2019-11 (A-20), Enable Physicians to Treat Cannabis Dependence, as amended (with title change):

Title Change: Resolution 09.2019-11 (A-20), ~~Enable Physicians~~ Federal Initiative to Treat Cannabis Dependence

RESOLVED, that ISMS urges the National Institutes of Health (NIH) to award appropriate incentive grants to universities, pharmaceutical companies and other entities capable of developing such medications treatment options for cannabis dependence; and be it further

RESOLVED, that ISMS advocate that the cost of grants to incentivize the development of treatment options for cannabis dependence be financed by taxes on those who profit from selling cannabis; and be it further

RESOLVED, that the Illinois AMA delegation submit a resolution asking the AMA to urge the NIH to awards appropriate incentive grants to universities, pharmaceutical companies and other entities capable of developing treatment options for cannabis dependence; and that the AMA advocate that the cost of grants to incentivize the development of treatment options for cannabis dependence be financed by taxes on those who profit from selling cannabis.